Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
25
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Supernus Pharmaceuticals, Inc.